Capmatinib adn lobratinib combinaiton for non-small cell lung cancer – pro
There is an integrated molecular analysis of serial tumor and plasma samples by Schneidier et al, but I did nto find other literature on the use of this combination. There is a lack of clinical evidence regarding the effectiveness of this drug for this indication as published in authoritative, peer-reviewed medical and scientific literature.
Schneider JL, Shaverdashvili K, Mino-Kenudson M, Digumarthy SR, Do A, Liu A, Gainor JF, Lennerz JK, Burns TF, Lin JJ. Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution. NPJ Precis Oncol. 2023 Nov 3;7(1):116. doi: 10.1038/s41698-023-00464-y. PMID: 37923925; PMCID: PMC10624912.
Chung EK, Yong SH, Lee EH, Kim EY, Chang YS, Lee SH. New Targeted Therapy for Non-Small Cell Lung Cancer. Tuberc Respir Dis (Seoul). 2023 Jan;86(1):1-13. doi: 10.4046/trd.2022.0066. Epub 2022 Oct 5. PMID: 36196556; PMCID: PMC9816494.